Leerink raised its target to USD 8 for Zentalis Pharmaceuticals stock

Published on 10/16/2026 at 00:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zentalis reported a USD 0.59 GAAP loss per share in the second quarter. Zentalis Pharmaceuticals stock has data dates on October 23 and October 26.

Clinical milestones and earnings pressure

Leerink Partners changed its rating on October 5, 2026, while setting an USD 8.00 target.
Zentalis reported a USD 0.59 GAAP loss per share for the second quarter against USD 0.49 expected.
Clinical data presentations are scheduled for October 23, 2026, and October 26, 2026.

ZNTL, US98943L1070, Illustration mit AI erstellt.

Zentalis Pharmaceuticals (ISIN US98943L1070) faces two October clinical milestones after Leerink Partners raised its price target from USD 4.00 to USD 8.00 on October 5, 2026. The revised view centers on azenosertib, the company candidate being tested as an oral WEE1 inhibitor for advanced cancers.

The target change is the clearest current analyst signal for Zentalis. According to Markets Insider, Leerink also upgraded its rating from Market Perform to Outperform. The move puts the USD 8.00 target above the USD 5.00 target reported for Wells Fargo coverage in October, although the two research views are not directly comparable because the sources use different dates.

Three financing and research steps

Over the past year, Group Walters bought 4,335,000 Zentalis shares for USD 15,172,500 on August 14, 2026, according to MarketBeat. On October 1, 2026, the company granted options covering 62,000 shares to three new employees, as reported by Yahoo Finance. Leerink then published its October 5 target change, completing the recent sequence.

What does October data mean?

The clinical readouts matter because the second-quarter financial profile remains heavily loss-making. Zentalis reported a quarterly GAAP net loss of USD 77.64 million for the period ended June 30, 2026, compared with USD 26.87 million in the same period of the prior year, according to The Globe and Mail. The company also reported a GAAP loss of USD 0.59 per share against a USD 0.49 consensus estimate in the second quarter, according to MarketBeat.

Two clinical dates ahead

Zentalis is scheduled to present overall survival data from Part 1b of its DENALI study at the European Society for Medical Oncology Congress on October 23, 2026. A Phase 3 ASPENOVA trial-in-progress poster is scheduled for October 26, 2026, according to Yahoo Finance.

Market value stays modest

Zentalis had a market capitalization of USD 159.5 million on October 15, 2026. Its 52-week range was USD 1.21 to USD 6.95 on that date, leaving the upcoming clinical evidence as the principal measurable catalyst for the biotechnology company.